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RNA-binding proteins (RBPs) have been widely recognized for their pivotal role in the 
regulation of post-transcriptional processes. Particularly, their complexes with RNA are involved in 
numerous dysfunctions (i.e., cancer, inflammation, and neurodegeneration) and thus pose the 
interesting question of whether they could be used as therapeutic targets with clinical relevance [1].  
The research efforts of our team in this field have been dedicated to the identification of 
compounds able to modulate protein–RNA interactions, with a special focus on the ELAV 
(embryonic lethal abnormal vision) protein family [2,3]. Our first medicinal chemistry synthetic 
campaign exploited a structure-based approach for the design of novel HuR ligands based on 
different scaffolds. The synthesis of representative compounds of each series was accomplished 
through multicomponent reactions or equally efficient processes. Afterwards, the structural 
elucidation of their interaction with HuR was carried out according to an STD (saturation transfer 
difference)-NMR and in silico combined strategy [4].  
In this communication, we move a step forward in understanding the structural features 
essential for the interaction with HuR. The information thus obtained represents the basis to identify 
compounds able to interfere with HuR–RNA complexes, therefore modulating gene expression. 
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